

Reg No : 202409033860629  
 Name : Y P M De Silva  
 MRN No : -  
 Referred Dr : Dr Mahendra Perera

Sex / Age : Female / 73Y  
 Reg Date : 20/09/2024 04:55 PM  
 Report Date : 24/09/2024 01:08 PM

**HISTOPATHOLOGY**

**PD-L1(IHC)**

Lab no: HLD/IHC-762-24

**Specimen**

Specimen type: Paraffin block no: XH28679 A  
 Specimen site: Gall bladder.  
 Screening done by: Light microscopy

**Procedure** IHC was performed by DAKO Platform on the formalin fixed paraffin block.

**Interpretation**

Markers	Pattern	Intensity	Score(Tumor Proportion Score-TPS)
PD-L1 (22C3)	Cytoplasmic staining in tumor cells seen.	Moderate staining	30-35%

Markers	Pattern	Intensity	Score(Combined Positive Score-CPS)
PD-L1 (22C3)	Staining in tumor and lymphocytes.	Moderate staining	Less than 40%

**Biomarker summary**

**PD-L1(22C3) by immunohistochemistry shows staining in tumor cells and in lymphocytes with TPS score of 30-35% and CPS score of less than 40%.**

**Interpretation :**

**Guidelines for therapy indications**

Condition	Score Cut off
First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC	TPS more than or equal to 1%
Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC	TPS more than or equal to 1%
First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC	CPS more than or equal to 1%
Advanced Esophageal or GEJ Carcinoma	CPS more than or equal to 10%
Advanced Cervical Cancer	CPS more than or equal to 1%
Advanced Triple-Negative Breast Cancer	CPS more than or equal to 10%

- PDL-1 Staining / expression is defined as complete or partial circumferential linear plasma membrane staining at any intensity that can be differentiated from background and diffuse cytoplasmic staining. Only cytoplasmic staining is not considered significant.

- The percentage of tumor cells that exhibit PDL-1 expression is recorded.
- Testing for PD-L1 should be done at time of diagnosis or prior to second line or greater treatment.

**Indications for KEYTRUDA That Require PD-L1 Testing**

- Advanced NonSmall Cell Lung Cancer (NSCLC)
- Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Reg No : 202409033860629  
Name : Y P M De Silva  
MRN No : -  
Referred Dr : Dr Mahendra Perera

Sex / Age : Female / 73Y  
Reg Date : 20/09/2024 04:55 PM  
Report Date : 24/09/2024 01:08 PM

---

**HISTOPATHOLOGY**

---

- c. Advanced Esophageal or GEJ Carcinoma
  - d. Advanced Cervical Cancer
  - e. Advanced Triple-Negative Breast Cancer (TNBC)
- 

**End of Report**



**Dr. Prabhu Meganathan**  
Senior Consultant Pathologist  
MBBS, MD, KMC78087